Extended-Release Buprenorphine Not Necessarily Cost-Effective
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 19, 2023 -- For patients with opioid use disorder (OUD), treatment with extended-release buprenorphine is not cost-effective when transmucosal buprenorphine is available, according to a study published online Sept. 13 in JAMA Network Open.
Juliet M. Flam-Ross, from Boston Medical Center, and colleagues examined the cost-effectiveness of extended-release buprenorphine versus transmucosal buprenorphine. The evaluation simulated the lifetime of a closed cohort of 100,000 individuals with OUD receiving or not receiving opioid agonist treatment with buprenorphine.
The researchers found that treatment with transmucosal buprenorphine yielded an incremental cost-effectiveness ratio of $19,740 per quality-adjusted life year (QALY) compared with no medication treatment. Treatment with extended-release versus transmucosal buprenorphine yielded lower effectiveness by 0.03 QALYs per person at higher cost. Transmucosal buprenorphine was the preferred strategy 60 percent of the time in probabilistic sensitivity analyses. Compared with treatment with transmucosal buprenorphine, treatment with extended-release buprenorphine was cost-effective at a willingness-to-pay threshold of $100,000 per QALY only after substantial changes in key parameters.
"The ongoing nationwide surge in opioid overdose deaths underscores the need for a broad menu of effective treatments to address the diverse needs of all patients," the authors write. "Our findings on important thresholds in two key parameters, namely cost and retention, might be helpful to policy makers."
One author disclosed ties to industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Rapid Procedure Noninferior for Extended-Release Naltrexone Initiation
THURSDAY, May 9, 2024 -- For patients with opioid use disorder (OUD), a rapid procedure (RP) is noninferior to a standard procedure for initiation of extended-release (XR)...
321,566 Children Lost a Parent to Drug Overdose in 2011 to 2021
WEDNESDAY, May 8, 2024 -- From 2011 to 2021, an estimated 321,566 children lost a parent to drug overdose in the United States, according to a study published online May 8 in JAMA...
Maltreatment as a Child Ups Odds of Substance Use Admissions by Age 40 Years
WEDNESDAY, May 8, 2024 -- People with a history of child maltreatment (CM) appear to have significantly higher odds of inpatient admissions for alcohol use disorders (AUDs) and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.